LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Home・Akcijų sąrašas・Essa Pharma Inc

Essa Pharma Inc

Uždarymo kaina

1.71 1.79

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.68

Max

1.71

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.2M -6.4M
Pelnas, tenkantis vienai akcijai	-0.195
Darbuotojai	35
EBITDA	-2.2M -8.5M

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.3M 75M
Ankstesnė atidarymo kaina	-0.08
Ankstesnė uždarymo kaina	1.71

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.7 / 1.72 Palaikymas ir pasipriešinimas

Essa Pharma Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-15 22:52; UTC

Uždarbis

Pagrindinės rinkos jėgos

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

2025-05-15 20:37; UTC

Svarbiausios naujienos

Uždarbis

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

2025-05-16 00:00; UTC

Rinkos pokalbiai

Xero Bull Stays Positive on Cost Outlook -- Market Talk

2025-05-15 23:47; UTC

Rinkos pokalbiai

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

2025-05-15 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-15 23:38; UTC

Rinkos pokalbiai

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025-05-15 23:14; UTC

Svarbiausios naujienos

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

2025-05-15 22:46; UTC

Svarbiausios naujienos

Įsigijimai, susijungimai, perėmimai

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025-05-15 21:58; UTC

Uždarbis

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

2025-05-15 21:24; UTC

Uždarbis

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

2025-05-15 20:56; UTC

Rinkos pokalbiai

U.S. Spending Downturn Could Lie Ahead -- Market Talk

2025-05-15 20:54; UTC

Rinkos pokalbiai

Uždarbis

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

2025-05-15 20:54; UTC

Uždarbis

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

2025-05-15 20:51; UTC

Uždarbis

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

2025-05-15 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-05-15 20:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

2025-05-15 20:50; UTC

Uždarbis

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

2025-05-15 20:26; UTC

Svarbiausios naujienos

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

2025-05-15 20:25; UTC

Uždarbis

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Essa Pharma Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Essa Pharma Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.7 / 1.72Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.